Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
GXP OXYCODONE, OXYCODONE JL, OXYCODONE NH, OXYCODONE NHPL, OXYCODOR LIQUID, OXYCODOR, OXYLENUS, OXYCODONE CP, OXYCODONE AB, OXYCODONE GPPL, OXYCODONE MLP, GXP OXYCODONE LIQUID, OXYNDONE, OXYLENUS LIQUID , OXYCODONE GENPAR, OXYCODONE GPPL LIQUID, OXYCODONE
Product name
GXP OXYCODONE, OXYCODONE JL, OXYCODONE NH, OXYCODONE NHPL, OXYCODOR LIQUID, OXYCODOR, OXYLENUS, OXYCODONE CP, OXYCODONE AB, OXYCODONE GPPL, OXYCODONE MLP, GXP OXYCODONE LIQUID, OXYNDONE, OXYLENUS LIQUID , OXYCODONE GENPAR, OXYCODONE GPPL LIQUID, OXYCODONE NEO HEALTH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
oxycodone hydrochloride
Registration type
New generic medicine
Indication
OXYCODONE GENPAR, OXYCODONE NEO HEALTH, OXYCODONE NHPL, OXYNDONE are indicated for the management of opioid-responsive, moderate to severe pain.
GXP OXYCODONE, GXP OXYCODONE LIQUID, OXYCODONE GPPL, OXYCODONE GPPL LIQUID, OXYLENUS, OXYLENUS LIQUID, OXYCODONE JL, OXYCODOR, OXYCODOR LIQUID, OXYCODONE NH, OXYCODONE MLP, OXYCODONE CP, OXYCODONE AB are indicated for the management of opioid-responsive moderate to severe pain.